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A B S T R A C T   
Despite some approvals of antibody-drug conjugates for cancer therapy, their clinical success rate is un-
satisfactory because of very small therapeutic windows, influenced by on-target and off-target toxicities of 
conjugate and liberated toxin. Additional formats with systematically investigated molecular parameters must 
therefore be explored to increase their therapeutic window. Here we focused on the effective molecular weight. 
To generate conjugates with exactly defined drug loads and tunable pharmacokinetics, we used Designed 
Ankyrin Repeat Proteins (DARPins), fused to unstructured polypeptides of different lengths, to produce proteins 
with any desired half-life, to identify those with the best efficacy. We generated an EpCAM-targeting DARPin- 
MMAF conjugate, fused to PAS or XTEN of different lengths, and a matched series of controls of a non-binding 
DARPin to account for the enhanced permeability and retention (EPR) effect, covering half-lives of minutes to 
20.6 h in mice. All conjugates were produced at high purity, and demonstrated high specificity and cytotoxicity 
in human tumor cell cultures, with IC50 values in the low nM range, independent of the polypeptide type and 
length. Due to their more facile purification, the PASylated conjugates were tested in nude mice bearing HT29 
tumor xenografts. Independent of their size, all PASylated conjugates were very well tolerated after repeated 
systemic administration of 300 nmol/kg. We found that the conjugates with intermediate size and half-life 
showed the strongest anti-tumor effects, and deduced that this effect is a compromise of serum half-life and 
diffusion within the tumor, as on-rates and affinities are essentially identical, with extravasation playing only a 
very minor role.   
1. Introduction 
Tumor targeting with antibody-drug conjugates (ADCs) has 
emerged as a promising approach to more specific cancer therapy. By 
combining the specificity of a cell-binding domain with the destructive 
potential of a potent cytotoxin, the side-effects typically associated with 
conventional chemotherapeutics can be decreased [1]. Despite of re-
search spanning several decades, only eight ADCs have been approved 
by the FDA (www.fda.gov) for the treatment of several malignancies, 
including relapsed acute myelogenous leukemia (AML), HER2-positive 
metastatic breast cancer, and relapsed or refractory diffuse large B-cell 
lymphoma (DLBCL). Numerous other ADCs are currently under pre-
clinical and clinical investigation for various oncological indications 
and several candidates are expected to become approved soon [2]. 
Nonetheless, the key challenge in developing ADCs remains to find a 
therapeutic window, in other words, a suitable combination of efficacy 
and tolerable on-target and off-target toxicity of both the whole 
conjugate and the liberated toxin molecules. An important considera-
tion is also their biodistribution and pharmacokinetics. Antibodies have 
limited potential to penetrate solid tumors and homogeneously dis-
tribute in the tissue [3], which consequently lowers efficacy and favors 
development of drug resistance. Antibodies have a very long half-life, 
but it is largely unknown what pharmacokinetic properties are needed 
to improve tumor localization and to maximize efficacy and toler-
ability. 
For experiments designed to modulate the pharmacokinetic para-
meters and optimize the therapeutic window of drug conjugates by 
engineering, conventional ADCs with their intrinsically long serum 
half-life and — typically — heterogeneous drug-to-antibody ratios 
(DAR) are not ideal. Additionally, their bivalent nature, which might 
lead to unintended receptor activation especially after loss of the drug, 
is another challenge [4]. Finally, the development of safe and effica-
cious ADCs is thwarted by the molecular complexity of the IgG format, 
and the fact that the site of conjugation and drug-to-antibody ratios 
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(DAR) will greatly affect aggregation propensity and stability, drug 
release and efficacy. This further complicates analysis, even though 
attempts to engineer functionally improved ADCs with increased site- 
specificity of drug conjugation and higher linker stability have been 
made [5]. 
The fundamental downsides of conventional ADCs have raised in-
terest in alternative non-IgG binding scaffolds for the use in tumor 
targeting, such as Designed Ankyrin Repeat Proteins (DARPins), 
Adnectins, Affibodies and Kunitz domains, all of which are much better 
suited to optimally engineer the desired pharmacokinetic properties 
[6,7]. DARPins have been selected against a wide range of tumor 
markers using phage and ribosome display. Furthermore, they display 
favorable biophysical and biochemical properties with high thermo-
dynamic stability, and can be expressed in the cytoplasm of Escherichia 
coli (E. coli) in high amounts, allowing cost-effective production at large 
scales [8]. The DARPin scaffold is by design devoid of internal cysteines 
and allows for extensive engineering, tolerating modifications at its N- 
and C-terminus [9]. A unique cysteine can be easily introduced at any 
place in the sequence, including the DARPins' C-terminus, for defined, 
site-specific drug conjugation, e.g., for the facile generation of mole-
cularly defined DARPin-drug conjugates with well-defined drug loads 
[10]. 
On the other hand, due to their small size and lack of FcRn re-
cycling, DARPin-drug conjugates have very short serum half-lives of 
only a few minutes [10,11] and in unmodified form, they consequently 
suffer from poor tumor localization [12]. This limitation can in prin-
ciple be overcome by conjugation to PEG [11], fusion to Fcγ or serum 
albumin [13,14], to albumin-binding proteins [15,16] or to un-
structured half-life extension modules like PAS or XTEN [12,17,18]. On 
the other hand, longer circulation times might be assumed to decrease 
tolerability of drug conjugates due to off-target toxicity. Furthermore, 
as known from antibodies, large size inevitably impairs tissue pene-
tration and hence anti-tumor efficacy [19,20]. Presumably, an optimal 
size exists for the two opposing effects: the benefit of increased tumor 
localization of cytotoxins due to longer persistence in the circulation 
versus the hindered diffusion of the whole drug conjugate in the tumor 
[21,22] and perhaps decreased tolerability. 
To study these dependencies, and optimize tumor to non-tumor 
ratios and increase tumor penetration to optimize the therapeutic 
window, it is essential to have a very well-defined, controllable system. 
DARPins can be genetically fused to half-life extension modules of 
various lengths and site-specifically conjugated to cytotoxins in a facile 
manner [9,12]. They thus offer the opportunity to rigorously study the 
biochemical, pharmacokinetic, and therapeutic behavior as a function 
of molecular parameters. 
Here we systematically investigated how apparent molecular size 
affects the tolerability and anti-tumor efficacy of a series of DARPin- 
cytotoxin conjugates (Ec1-MMAF), targeting the epithelial cell adhesion 
molecule (EpCAM) on solid tumors. Ec1-MMAF was produced with a 
defined drug-to-protein ratio of 1.0 and PASylated or XTENylated to 
different molecular sizes. A series of matching control molecules was 
produced which have no affinity for tumor cells, to account for the 
enhanced permeability and retention (EPR) effect of larger molecules. 
The efficacy and tolerability in tumor cell cultures and in tumor-bearing 
mice was systematically compared as a function of molecular para-
meters. We found that the anti-tumor effect was more pronounced for 
the medium size conjugates than for the largest one, and we examined 
explanations for this behavior. 
2. Materials and methods 
2.1. Construction of polypeptide-DARPin fusion proteins containing a single 
C-terminal cysteine for drug conjugation 
The plasmid pQIq encoding the EpCAM-binding DARPin Ec1 [23] 
was modified (Fig. 1A) at the DARPin 5′-end by introducing a gene 
fragment encoding the superfolder green fluorescent protein (sfGFP) 
[24], followed by a Tobacco Etch Virus (TEV) cleavage site (ENLYFQG) 
and a FLAG-tag (DYKDDDDK) including a BmtI restriction site at the 3′- 
end. PAS (PAS300, PAS600, PAS900) and XTEN (XTEN288, XTEN576, 
XTEN864) sequences were introduced between the FLAG-tag and the 
DARPin by cloning via BmtI and BamHI restriction sites, as previously 
reported [12]. For site-specific conjugation of a cytotoxin to the fusion 
proteins, the 3′-end of the DARPin was exchanged with a gene fragment 
encoding a single cysteine within a GCG-motif in front of a TEV pro-
tease-cleavable His6-tag (GCGENLYFQGHHHHHH). To generate non- 
binding fusion proteins as controls, DARPin Ec1 was replaced by 
DARPin Off7 [25], recognizing the E. coli maltose-binding protein. All 
constructs were expressed under the control of a T5 promoter (Fig. 1A). 
2.2. Expression and purification of maleimide-reactive polypeptide-DARPin 
fusion proteins in large scale 
All single-cysteine-containing DARPins and polypeptide-DARPin 
fusion proteins were expressed in E. coli BLR in ZYM-5052 [26] auto-
induction media as previously reported [12]. After expression, the E. 
coli cells were pelleted by centrifugation at 4000 × g and washed by 
resuspension in PBS pH 7.4. For purification, cell pellets were re-
suspended in 50 mM Tris-HCl pH 8.0, 400 mM NaCl (TBS400), sup-
plemented with 3 mg/mL lysozyme, 100 μg/mL DNase I and lysed by 
sonication. Following sonication, lysates were centrifuged (21,000 × g, 
30 min, 4 °C) and the supernatants were applied to a 500 mL Ni-NTA 
Superflow (Qiagen) metal affinity column connected to an Äkta Pure 
(GE Healthcare) FPLC system. The resin was washed with 50 mM Tris- 
HCl pH 8.0, 20 mM imidazole, in turn supplemented with 400 mM 
NaCl, 1 M NaCl or 20 mM NaCl, respectively, until the signal baseline at 
280 nm was reached. After stringent washing, the proteins were eluted 
in PBS pH 7.4, 500 mM imidazole, collecting the eluate in fractions. 
Fractions containing the fusion proteins were pooled and applied to 
25 mL GFP affinity-columns [27] and washed with each 15 CV of 
TBS400 and 15 CV TBS400 supplemented with 5 mM ATP, 5 mM 
MgCl2. The GFP affinity-columns were equilibrated with 25 mM Tris- 
HCl pH 8.0, 300 mM NaCl, 0.5 mM EDTA, 1 mM DTT, and TEV protease 
(S219V mutant) [28], produced in-house, was added to a final con-
centration of 100 μg/mL. After incubation overnight at 4 °C, the cleaved 
proteins (with removed GFP- and His-tag) were eluted and concentrated 
by ultrafiltration (Amicon Centrifugal Filter Units, Millipore). Con-
centrated proteins were polished by preparative size exclusion chro-
matography on an Äkta Pure FPLC system (GE Healthcare) using a 
custom-made Superose 6 pg XK 16/60 (GE Healthcare) column and PBS 
pH 7.4, 300 mM NaCl, 5 mM DTT as running buffer. Fractions con-
taining the desired proteins were pooled based on their UV traces and 
concentrated by ultrafiltration (Amicon Centrifugal Filter Units, Milli-
pore). 
2.3. Preparation of DARPin-MMAF and polypeptide-DARPin-MMAF 
conjugates 
For site-specific conjugation of MMAF to the C-terminal cysteine of 
purified proteins, mcMMAF (HY-15578, MedChemExpress) was dis-
solved in anhydrous DMSO to a concentration of 5 mM. Protein samples 
were spiked with freshly dissolved DTT to a final concentration of 
7.5 mM and reduced while shaking at 25 °C for 30 min. To remove DTT 
from the samples, the buffer was exchanged to rigorously degassed PBS 
pH 7.4, 1 mM EDTA on a HiPrep™ 26/10 Desalting column (GE 
Healthcare) connected to an Äkta Explorer (GE Healthcare) FPLC 
system. Desalted protein samples (15–30 μM) were mixed with a 2-fold 
molar excess of mcMMAF over reduced cysteine. For conjugation, the 
reaction was incubated for 4 h at 25 °C with shaking. The conjugation 
mixtures were then quenched by addition of a 5-fold molar excess of 
DTT over maleimide and incubated for 15 min at 25 °C with shaking. 
All steps were carried out under an argon atmosphere. 
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2.4. Small-scale purification of DARPin-MMAF and polypeptide-DARPin- 
MMAF conjugates for in vitro cell viability assays 
For small-scale purification, DARPin-MMAF and polypeptide- 
DARPin-MMAF conjugates were purified by hydrophobic interaction 
chromatography (HIC). Briefly, a RESOURCE ISO (GE Healthcare) 
column was connected to an Äkta Micro FPLC system. Samples were 
diluted in 2× Buffer A (25 mM Na-phosphate pH 7.0, 2.7 M (NH4)2SO4) 
to adjust the ammonium sulfate concentration to that in the running 
buffer A (25 mM Na-phosphate pH 7.0, 1.35 M (NH4)2SO4). Samples 
with protein concentrations of 0.3 mg/mL were loaded onto the HIC 
column at a flow rate of 0.5 mL/min at 10 °C. Conjugates were eluted in 
a linear gradient of 5%B/min (Buffer B = 25 mM Na-phosphate 
pH 7.0). Fractions containing the conjugate were pooled and con-
centrated using Amicon Ultra Filter Tubes (Millipore). Purity was 
monitored by SDS-PAGE and analytical HIC, and was confirmed by ESI- 
MS. 
2.5. Large-scale purification of DARPin-MMAF and PAS-DARPin-MMAF 
conjugates for in vivo tolerability and treatment studies 
For large-scale purification of the MMAF conjugates from residual 
DTT, EDTA, quenched MMAF and other impurities, the conjugates were 
further polished by anion exchange chromatography. Briefly, conjuga-
tion mixtures were diluted 2-fold in 20 mM Tris-HCl pH 8.0 and were 
loaded onto a 1 mL Resource™ Q (GE Healthcare) anion exchange 
column connected to an Äkta Explorer (GE Healthcare) FPLC system 
running with Buffer A (20 mM Tris-HCl, 20 mM NaCl). Impurities were 
separated from the desired MMAF-conjugates by rigorous washing and 
stepwise elution with increasing percentage of Buffer B (20 mM Tris- 
HCl pH 8.0, 1 M NaCl). All steps were performed with a flow rate of 
3–4 mL/min. Purity of samples was monitored by SDS-PAGE and ana-
lytical HIC, and was confirmed by ESI-MS. 
2.6. Endotoxin removal 
For endotoxin removal, purified proteins were applied to an 
EndoTrap HD (product discontinued, Hyglos GmbH) affinity resin ac-
cording to the manufacturer's instructions. The buffer of eluted protein- 
MMAF conjugates was exchanged to endotoxin-free Dulbecco's PBS 
(Millipore) by PD-10 desalting columns (GE Healthcare). Endotoxin 
content was determined with an EndoSafe Portable Test System 
(Charles River Laboratories) using PTS test cartridges with 0.5–0.005 
EU/mL sensitivity. 
Fig. 1. Design and characterization of PASylated DARPin Ec1-MMAF conjugates. A) Schematic representation of expression constructs and a Rosetta-simulated 
exemplary model of a PAS300-DARPin-MMAF conjugate. B) SDS-PAGE of purified MMAF-conjugates, C) detection of the N-terminal FLAG-Tag by Western blotting 
with chemiluminescent immunodetection: lane 1) Ec1-MMAF, 2) PAS300-Ec1-MMAF, 3) PAS600-Ec1-MMAF, 4) PAS900-Ec1-MMAF. D) Analytical characterization 
of non-conjugated protein (dashed line) and purified protein-MMAF conjugates (filled line) by hydrophobic interaction chromatography. E) Analysis of purified 
protein-MMAF conjugates by ESI-MS, the values are shown in Table 1. 
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2.7. SDS-PAGE analysis 
Equimolar amounts (113 pmol) of protein were analyzed by non- 
reducing SDS-PAGE using NuPAGE™ 4–12% Bis-Tris Protein Gels 
(Thermo Fisher Scientific) with NuPAGE™ MOPS SDS running buffer 
(Thermo Fisher Scientific). As molecular weight standard, PageRuler™ 
Prestained Protein Ladder (Fermentas) was used. Gels were stained 
with Coomassie Brilliant Blue R250 (Sigma-Aldrich). 
2.8. Western blotting and immunodetection of the N-terminal FLAG-tag 
For detection of the N-terminal FLAG-tag, 13 pmol of protein was 
separated on a NuPAGE™ 4–12% Bis-Tris Protein Gel (Thermo Fisher 
Scientific) and subsequently blotted to a Whatman™ 0.45 μm Protran 
Nitrocellulose membrane (Millipore) using a Trans-Blot® SD electro-
phoretic transfer cell (BioRad) and Towbin blotting buffer. The mem-
brane was then blocked for 1 h with PBS-TB (PBS pH 7.4, 0.1% Tween- 
20, 5% w/v nonfat-dried milk) and washed three times with PBS-T (PBS 
pH 7.4, 0.1% Tween-20). Next, the membrane was incubated for 1 h 
with mouse anti-FLAG M2 primary antibody (Sigma-Aldrich, PN 
F3165) diluted 1:1000 in PBS-TM (PBS pH 7.4, 0.1% Tween-20, 0.5% 
w/v nonfat-dried milk). After washing three times with PBS-T, the 
membrane was incubated for 1 h with goat anti-mouse IgG H + L 
horseradish peroxidase conjugate (Thermo Fisher Scientific, PN 31438) 
diluted 1:5000 in PBS-TM. After stringently washing with PBS-T, PBS, 
and ddH2O, SuperSignal® West Pico Chemiluminescent Substrate 
(Thermo Fisher Scientific, PN 34077) was prepared according to the 
manufacturer's instructions and chemiluminescence was measured 
using a Fusion FX spectra imaging device (Vilber). All steps were con-
ducted at room temperature. 
2.9. Analytical hydrophobic interaction chromatography 
Purified conjugates were analyzed on a TSKgel Butyl-NPR (L × ID 
3.5 cm × 4.6 mm, 2.5 μm particle size, Tosoh Bioscience) hydrophobic 
interaction chromatography column connected to a 1260 Infinity HPLC 
system (Agilent Technologies). Samples containing 8–16 μg protein 
conjugate were spiked with ammonium sulfate to a final concentration 
of 1.5 M (NH4)2SO4 and loaded onto the column running with Buffer A 
(25 mM Na-phosphate pH 7.0, 1.5 M (NH4)2SO4). For analysis, the 
proteins were eluted by a linear gradient of 33–83% Buffer B (25 mM 
Na-phosphate pH 7.0) in 50 min at a flow rate of 0.6 mL/min at 25 °C. 
UV absorbance was monitored at 280 nm and 230 nm. Data were 
analyzed using the OpenLab CDS ChemStation Edition Software 
(Version 1.3.4., Agilent Technologies). 
2.10. Electrospray ionization mass spectrometry (ESI-MS) 
Protein masses were determined by time-of-flight (TOF) ESI-MS at 
the Functional Genomics Center Zurich (FGCZ). Prior to ESI-MS ana-
lysis, samples were desalted by C4 ZipTip (Millipore, USA) reversed 
phase chromatography and eluted in MeOH:2-propanol:0.2% formic 
acid (30:20:50). The eluates were infused through a fused silica capil-
lary (inner diameter 75 μm) at a flow rate of 1 μL/min and sprayed 
through a PicoTip with an inner diameter of 30 μm (New Objective, 
USA). Nano ESI-MS analysis of the samples was performed on a Synapt 
G2_Si mass spectrometer (Waters, UK) and the data were recorded with 
MassLynx 4.2. Software (Waters, UK). Mass spectra were acquired in 
positive-ion mode by scanning an m/z range from 100 to 5000 Da with 
a scan duration of 1 s and an interscan delay of 0.1 s. The spray voltage 
was set to 3 kV, the cone voltage to 40 V, and the source temperature to 
80 °C. The recorded m/z data were then deconvoluted into mass spectra 
by applying the maximum entropy algorithm MaxEnt1 (MaxLynx) with 
a resolution of the output mass of 0.5 Da/channel and Uniform 
Gaussian Damage Model at the half height of 0.7 Da. 
2.11. Analysis of the binding kinetics by surface plasmon resonance 
spectroscopy (SPR) 
The binding kinetics of PASylated and XTENylated DARPin Ec1- 
MMAF conjugates and unfused Ec1-MMAF to the purified extracellular 
domain of human EpCAM (hEpEX) were determined on a ProteOn™ 
XPR36 instrument (BioRad). The ligand protein hEpEX was expressed, 
purified and enzymatically biotinylated as previously described [29]. 
First, two ligand channels of a NeutrAvidin-functionalized chip (Pro-
teOn™ NLC Sensor Chip, BioRad) were coated with 500 RU of bioti-
nylated hEpEX in PBS pH 7.4, 0.005% Tween 20, 3 mM EDTA. Fol-
lowing a buffer injection for baseline stabilization, a serial dilution of 
the polypeptide-DARPin fusion proteins (162 nM – 0.33 pM) was in-
jected on separate ligand channels in duplicates. The flow rate of all 
steps was 60 μL/min, the association time and the dissociation time 
were 400 s and 2500 s, respectively. The chip surface coated with li-
gand was regenerated between analyte runs by two pulses of 25 μL 
100 mM H3PO4 for 25 s. The sensorgrams were double-referenced by 
subtraction of interspot signals and a blank analyte channel. Data was 
fitted to a 1:1 Langmuir binding model and analyzed using the Pro-
teOn™ Manager Software (Version 3.1.0.6, BioRad). 
2.12. Cell lines and cell culture conditions 
The EpCAM-positive human colon adenocarinoma cell line HT29 
and the EpCAM-positive human breast adenocarcinoma cell line SKBR3 
were obtained from DSMZ (German Collection of Microogranisms and 
Cell Cultures) and ATCC (American Type Culture Collection), respec-
tively. The human embryonic kidney cell line HEK293T (ATCC) was 
used as EpCAM-negative control. HT29 and HEK293T cells were cul-
tured in Dulbecco's Modified Eagle's medium (DMEM), SKBR3 cells 
were cultured in RPMI 1640 medium. All media were supplemented 
with 10% (v/v) heat-inactivated fetal calf serum (Amimed) and 1% (v/ 
v) penicillin-streptomycin (Sigma-Aldrich). Cells were tested for human 
and murine pathogens (IDEXX BioResearch) and cultivated at 37 °C in a 
humidified atmosphere containing 5% CO2. 
2.13. Cell viability assay 
The cytotoxicity of MMAF-conjugates against EpCAM-positive and 
-negative cells was tested in colorimetric XTT cell proliferation assays 
(BioFroxx, PN 1167TT000). Cells were grown to a confluency of 
80–90%, trypsinized and diluted in fresh medium. Cell counts were 
determined with a CASY®TT cell counter and seeded into 96-well cell 
culture plates at a density of 5000 cells per well in 100 μL of medium, 
and grown for 24 h at 37 °C, 5% CO2. The medium was then replaced by 
dilution series of the protein-MMAF conjugates or free MMAF in 50 μL 
culture medium. To normalize the response, cells treated with 5 mg/mL 
hygromycin B were used as positive control, non-treated cells were used 
as negative control. All conditions were analyzed in triplicates. After 
72 h, the medium was aspirated and replaced by 50 μL of XTT reagent 
prepared according to the manufacturer's instructions, and with 50 μL 
fresh medium. After incubation for 1–2.5 h at 37 °C, 5% CO2, UV ab-
sorbance was measured at 463 nm and 670 nm reference wavelength 
with an Infinite® M1000 plate reader (Tecan). Dose-response curves 
with variable slopes were fitted to all data points with the equation 
(y = ymin + ((ymax-ymin)/(1 + 10(log(IC50)-x)·HillSlope)) using the 
GraphPad Prism software (Version 8.1.2. (441)), where y is the nor-
malized absorption, x is the drug conjugate concentration, ymin and ymax 
are the bottom and top plateau. The IC50 value is the concentration of 
drug at which cell viability was decreased by 50%. 
2.14. Mice 
Female Crl:CD1-Foxn1nu mice were purchased from Charles River 
Laboratories and housed under sterile conditions according to the 
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guidelines of the veterinary ordinance of the Kanton of Zurich 
(Switzerland) for animal welfare. 
2.15. Tolerability study 
To identify which doses and which dosing schedules are tolerated 
and safe, Crl:CD1-Foxn1nu mice (N = 3 per construct, 7 weeks of age) 
were injected into the tail vein with 200 nmol/kg and 300 nmol/kg 
MMAF, Ec1-MMAF, PAS300-Ec1-MMAF, PAS600-Ec1-MMAF, PAS900- 
Ec1-MMAF, and PBS every other day for five times. The body weight of 
the mice was monitored daily. One week after the last injection, mice 
were sacrificed and blood was collected by heart puncture. Blood was 
analyzed for blood cell counts of thrombocytes, leukocytes, ery-
throcytes, and levels of creatinine, total bilirubin, and aspartate ami-
notransferase (ASAT) and alanine aminotransferase (ALAT) activity in 
the blood were determined. All analyses were performed at the 
Veterinary Medical Laboratory of the University of Zurich according to 
IFCC (International Federation of Clinical Chemistry and Laboratory 
Medicine) standards. Data analysis was performed using the 
GraphPrism 8 software package (Version 8.1.2. (441)). Safe dosing was 
determined as dosing where the body weight did not reduce more than 
15% relative to the body weight at the day of the first injection, and 
blood counts, creatinine, bilirubin, ASAT and ALAT levels did not ex-
ceed critical levels. 
2.16. Anti-tumor efficacy 
Tumor xenografts were grown on the back of Crl:CD1-Foxn1nu mice 
aged 6 to 7 weeks by subcutanous injection of 8 × 106 HT29 cells, and 
anti-tumor efficacy was determined when tumors reached an average 
volume of 100 mm3. Tumor measurement was done double-blinded and 
mice were allocated into treatment groups with 6 mice each. All 
treatment groups were injected into the tail vein every other day for 
five times with 300 nmol/kg of MMAF, Ec1-MMAF, PAS300-Ec1- 
MMAF, PAS600-Ec1-MMAF, PAS900-Ec1-MMAF, Off7-MMAF, PAS300- 
Off7-MMAF, PAS600-Off7-MMAF, PAS900-Off7-MMAF in 150 μL PBS, 
or for untreated controls with 150 μL PBS. The body weight of mice was 
monitored daily by weighing and tumor size was measured with a di-
gital caliper. The tumor volume was calculated with the formula: (short 
diameter)2 × (long diameter) × 0.4. Euthanasia criteria were defined 
as body weight loss of more than 15% relative to the body weight at 
treatment start or as tumor size larger than 1000 mm3. After termina-
tion of treatment, body weight and tumor size were monitored three 
times per week for another 40 days. 
2.17. Statistical analysis of anti-tumor efficacy 
The one-way analysis of variance (ANOVA) test for multiple com-
parisons was performed using the GraphPrism 8 software package 
(Version 8.1.2. (441)). For comparison, the mean tumor volume on day 
18 after treatment start was chosen. The sigificance level was defined as 
P  <  0.05. 
3. Results 
We recently reported the fusion of PAS and XTEN polypeptides of 
various lengths to the EpCAM-targeting DARPin Ec1 and the control 
DARPin Off7 [12]. The polypeptides were produced with pairs of 
comparable lengths ranging from short (XTEN288 / PAS300), over in-
termediate (XTEN576 / PAS600) to very long (XTEN864 / PAS900) 
polypeptide sequences. The number refers to the amino acid residues 
(the PAS300 polypeptide, e.g., consists of 300 amino acid residues). 
Thereby, the hydrodynamic radii of the fusion proteins strongly in-
creased, extending the serum half-life of the unmodified DARPins in 
mice stepwise from 11 min up to 20.6 h, depending on the polypeptide 
length and type. Although the polypeptides (PAS and XTEN) showed 
the same pattern of organ distribution in mice, their localization to 
EpCAM-positive tumors was target-specific and correlated with mole-
cular size. 
3.1. Construction of generic polypeptide-DARPin fusion proteins and 
DARPins with single cysteines for site-specific drug conjugation 
To elucidate the relationship between a therapeutic protein's in vivo 
serum half-life, tolerability and efficacy, a unique cysteine was in-
troduced at the DARPins' C-terminus for conjugation. To this end, a 
segment 3′ of the DARPin was exchanged with a DNA fragment en-
coding a Gly-Cys-Gly (GCG) motif, followed by a TEV cleavage site and 
a hexahistidine-tag (GCGENLYFQG/GGSHHHHHH) (Fig. 1A). This al-
lowed the site-specific and defined addition of a single cytotoxin 
(maleimidocaproyl monomethyl auristatin F - mcMMAF [30]) to the 
proteins by maleimide-thiol conjugation (Fig. S1). 
3.2. Production of DARPins and polypeptide-DARPin fusions containing 
single cysteines for site-specific mcMMAF conjugation 
All DARPins and polypeptide-DARPin fusion proteins with a unique 
C-terminal cysteine were expressed in E. coli and purified using a pro-
tocol adapted from that recently reported [12]. After a four-step pur-
ification procedure, the proteins were highly pure and exhibited native 
biochemical and biophysical properties (Fig. S2, Fig. S3). Since the 
presence of His-tags on proteins can lead to increased liver accumula-
tion in mice [31,32], the polyhistidine-tags (His6-Tag) (Fig. 1A) on the 
proteins, used for purification by IMAC, were removed during the 
purification procedure by TEV cleavage. Successful removal of the 
polyhistidine-tags from the proteins was analyzed by Western blotting 
of purified proteins and immunodetection of His-tags. This showed the 
absence of any band except for the uncleaved controls (Fig. S4), con-
firming the successful removal and depletion of any His-tag containing 
protein. Detection of the N-terminal FLAG-tag on Western blots con-
firmed the prescence of only full-length proteins without any signs of 
degradation (Fig. S5). 
3.3. Preparation and characterization of highly pure and molecularly 
defined DARPin-MMAF and polypeptide-DARPin-MMAF conjugates 
For conjugating purified DARPins and polypeptide-DARPin fusions 
with a cytotoxin, maleimidocaproyl-functionalized monomethyl aur-
istatin F (mcMMAF) was conjugated to the unique cysteine introduced 
at the DARPins' C-terminus. The presence of mcMMAF in the proteins 
increased the hydrophobicity, incremented by the prescence of the 
caproyl linker, and it added an additional charge by the C-terminal 
carboxyl group of MMAF to the conjugates. Therefore, hydrophobic 
interaction chormatography (HIC) was used to purify MMAF conjugates 
on small scales (5–10 mg) for initial characterization and comparison of 
PASylated and XTENylated DARPin-MMAF conjugates in cell viability 
assays (XTT). Larger amounts (70–100 mg) for in vivo tolerability and 
treatment studies of PAS-DARPin-MMAF conjugates were purified by 
anion exchange chromatography (AEX). Both strategies, HIC and AEX, 
led to highly pure conjugate preparations (Fig. 1B,C,D,E, Fig. S6, S7). 
SDS-PAGE and Western blotting with N-terminal FLAG-tag detection 
confirmed the purity and integrity of the protein-MMAF conjugates 
(Fig. 1B,C, Fig. S6). Analytical HIC (Fig. 1D, Fig. S7) showed that all 
samples were mono-conjugated with drug-to-protein ratios (DPR) of 1.0 
and purities of > 95% (Table 1, Table S1) for all purified conjugates, 
and electrospray ionization mass spectroscopy (ESI-MS) (Fig. 1E, Fig. 
S7) confirmed the correct masses. 
To investigate the effect of C-terminal conjugation of mcMMAF to 
the DARPins and polypeptide-DARPin fusion proteins on EpCAM 
binding, binding kinetics were determined by surface plasmon re-
sonance measurements (SPR). Previous experiments showed that the 
fusion of PAS and XTEN polypeptides to the DARPins' N-terminus 
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altered the apparent equilibrium dissociation constant (KD) of DARPin 
Ec1 for EpCAM by slightly decreasing the association rate constant (ka), 
while keeping the dissociation rate constant (kd) unaltered [12]. As 
expected, SPR measurements showed that MMAF conjugation to the 
fusion proteins altered the association and dissociation rates only 
marginally within the error of the measurements and thus did not affect 
the equilibrium dissociation rates (KD) (Table 1, Table S1, Fig. S8); 
therefore, these binding kinetics equal those previously reported for 
non-conjugated polypeptide-DARPin fusion proteins [12]. 
3.4. Cytotoxicity of the polypeptide-MMAF conjugates in cell viability 
assays 
On EpCAM-positive cells, all conjugates with DARPin Ec1 were 
more cytotoxic than the corresponding non-binding control conjugates 
with DARPin Off7, typically by about 3 orders of magnitude, regardless 
of the type of polypeptide used for fusion (Fig. 2, Table 2, Fig. S9, Table 
S2). In contrast to their effects on EpCAM-positive cells, EpCAM-tar-
geting and non-targeting conjugates did not show measurable differ-
ences in cytotoxicity against EpCAM-negative HEK293T cells. Com-
pared to unmodified Ec1-MMAF (HT29: IC50 = 1.7 nM, SKBR3: 
IC50 = 0.07 nM), the polypeptide-Ec1-MMAF conjugates showed in 
general somewhat higher IC50 values on HT29 cells (IC50 = 6.3 nM – 
15.4 nM) and SKBR3 cells (IC50 = 0.9 nM – 4.8 nM) (Fig. 2, Table 2, 
Fig. S9, Table S2), and for the XTENylated conjugates this effect tended 
to slightly increase with the length (Fig. S9, Table S2). Nonetheless, the 
IC50 values for all polypeptide-Ec1-MMAF conjugates were very similar, 
and no correlation between cytotoxicity and polypeptide type could be 
found, indicating that PASylated and XTENylated DARPin-MMAF con-
jugates are equally potent. Furthermore, as shown for the PASylated 
conjugates, the differences in EpCAM-binding kinetics due to different 
polymer length (Fig. S8, Table S1) did not substantially affect the ki-
netics of intoxication, i.e., the time dependence of the XTT assay, and 
only marginally decreased potency (Fig. S10). 
3.5. Tolerability of PASylated DARPin-MMAF conjugates 
To investigate the relationship of very short (DARPin), short 
(PAS300-DARPin), intermediate (PAS600-DARPin) and long (PA900- 
DARPin) serum half-lives and tolerability of the conjugates with iden-
tical specificity and drug-to-protein ratio, nude mice were injected with 
increasing equimolar doses of conjugate, using the same injection 
schedule as for the treatment studies in tumor-bearing mice. To this 
end, mice (groups of 3 per construct and dose) were injected i.v. every 
other day for five times with 200 nmol/kg and 300 nmol/kg of the 
conjugates, and the body weight was monitored daily. One week after 
the last injection, aspartate aminotransferase (ASAT), alanine amino-
transferase (ALAT), creatinine and total bilirubin levels, as well as 
blood cell counts (erythrocytes, thrombocytes, leukocytes) were mea-
sured and compared to PBS-injected mice, and abnormal levels were 
used to assess toxicity. This dose-finding experiment provided a 
window of well-tolerated doses, which were later used in the treatment 
study. 
Daily monitoring of body weight and blood analysis after euthanasia 
indicated that both doses, 200 nmol/kg and 300 nmol/kg, were well 
tolerated. During the treatment for 10 days, the body weight did not 
decrease by more than 5% relative to the day of the first injection. 
ASAT, ALAT, creatinine and total bilirubin levels, as well as blood cell 
counts were within the expected range and comparable to the levels in 
PBS-injected mice (Fig. 3, Fig. S11). All measured parameters were also 
comparable with the reference levels of North American CD-1 nude 
mouse colonies reported by Charles River International (www.criver. 
com / CD-1 Nude Mouse Hematology and Biochemistry). In summary, 
this indicates that for all tested conjugates, doses of 200 nmol/kg and 
300 nmol/kg given every other day for five times were well tolerated. 
3.6. Anti-tumor efficacy of PASylated DARPin-MMAF conjugates 
The effect of molecular size and half-life on the anti-tumor efficacy 
was investigated in nude mice bearing EpCAM-positive HT29 tumor 
xenografts using the PASylated DARPin-MMAF conjugates of different 
length at the well tolerated doses and injection schedule described 
above. Control mice received PBS, free MMAF or the non-targeting 
conjugates Off7-MMAF, PAS300-Off7-MMAF, PAS600-Off7-MMAF and 
PAS900-Off7-MMAF. 
As expected, despite its high potency in vitro, no anti-tumor effect was 
seen with free MMAF and with the small DARPin Ec1-MMAF conjugate 
(Fig. 4A,B, Fig. S12). In contrast, with the EpCAM-targeting PASylated 
conjugates, pronounced anti-tumor effects were measured with PAS300- 
Ec1-MMAF and PAS600-Ec1-MMAF. Tumors started to rapidly shrink after 
the third injection and were hardly measurable at day 10 to 15 after the 
start of treatment when differences among the treatment groups were 
greatest. Thereafter, tumors regrew to an average volume of 100 mm3 on 
day 20 (Fig. 4A,C, Fig. S12). In both treatment groups, one out of six mice 
showed complete tumor regression. The strong anti-tumor effect of PAS300- 
Ec1-MMAF and PAS600-Ec1-MMAF is mirrored by an estimated overall 
survival of 33% at day 50 (Fig. 4B). 
Surprisingly, PAS900-Ec1-MMAF, the construct with the largest 
molecular size and longest serum half-life, was clearly less effective, 
and tumor growth could be controlled only during the first 10 days of 
treatment (Fig. 4A,C, Fig. S12). This difference in efficacy cannot be 
explained by delayed intoxication of the cells (Fig. S10). 
None of the non-targeting control conjugates (Off7-MMAF, PAS300- 
Off7-MMAF, PAS600-Off7-MMAF, PAS900-Off7-MMAF) inhibited 
tumor growth when compared to PBS (Fig. 4A,C, Fig. S12). The highly 
significant difference (P  <  0.0001) in efficacy of the various size- 
matched targeting and non-targeting conjugates reflects the window of 
specificity which can be reached with the treatments (Fig. 4C, Fig. S13). 
This demonstrates that designed modulation of molecular size and 
serum half-life is crucial to find the most effective drug conjugate for 
tumor targeting in a defined preclinical setting. It also allows us to draw 
some conclusions about the origins of this effect to guide the 
Table 1 
Biophysical characterization of PASylated and unmodified EpCAM-targeting DARPin Ec1.         
Construct MWcalca (kDa) MWexp_MSb (kDa) Purityc (%) kad (M−1 s−1) kdd (s−1) KDd (M)  
Ec1-MMAF 20.083 20.083  > 95% 2.14 × 105 1.39 × 10−5 6.48 × 10−11 
PAS300-Ec1-MMAF 45.007 45.007  > 95% 5.80 × 104 8.41 × 10−6 1.41 × 10−10 
PAS600-Ec1-MMAF 69.571 69.571  > 95% 4.11 × 104 1.08 × 10−5 2.62 × 10−10 
PAS900-Ec1-MMAF 94.136 94.136  > 95% 3.83 × 104 8.41 × 10−6 2.19 × 10−10 
a Molecular weights were calculated (MWcalc) with the ProtParam tool on the ExPASy server, based on the amino acid sequence of the polypeptide-DARPin fusion 
constructs. 
b Experimental molecular weights (MWexp_MS) were determined by ESI-MS (cf. Fig. 1E). 
c Purity was determined by analytical hydrophobic interaction chromatography on an HPLC system (cf. Fig. 1D). The purity is indicated as percentage and 
corresponds to the integrated conjugate peak area. 
d Binding kinetics to EpCAM (hEpEx) were determined by surface plasmon resonance (SPR, cf. Fig. S8).  
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development of optimal targeted conjugates. 
4. Discussion 
Antibody-drug conjugates (ADCs) have demonstrated improved 
therapeutic potential compared to standard chemotherapy, but clinical 
success rates are still far from satisfactory. To obtain acceptable ther-
apeutic windows, many interdependent molecular parameters have to 
be optimized at the same time. One of them is molecular size, as it 
influences pharmacokinetics and tissue distribution, and thus impacts 
on both efficacy and tolerability. Unfortunately, it would be difficult to 
systematically investigate this with conventional ADCs, especially if 
there is an additional complication from the range of drug-to-antibody 
ratios in the preparation, as opposed to molecularly defined species. 
Therefore, it has remained largely unknown how the optimal conjugate 
should be engineered with regard to molecular size and pharmacoki-
netics. 
Here, we generated EpCAM-targeting DARPin-MMAF conjugates as 
fusions with the unstructured polypeptides PAS or XTEN at different 
lengths to stepwise modify their size and hence serum half-life from 
11 min to 20.6 h in mice. Cytotoxicity, specificity, anti-tumor efficacy, 
and tolerability were investigated in preclinical models with human 
tumor cell lines in vitro and in vivo. 
4.1. Polypeptide-DARPin-MMAF conjugates can be produced as 
molecularly defined preparations 
Site-specific conjugation of antibodies with cytotoxins to obtain 
stoichiometrically defined payload numbers and ADC preparations with 
defined DARs are possible but challenging [5]. Alternative non-IgG 
scaffolds, such as DARPins, are promising for tumor targeting due to 
their favorable biophysical properties even as fusions and conjugates, 
and they thus offer a large freedom of engineering [8]. For instance, the 
DARPin scaffold allows site-directed engineering of reactive groups 
almost anywhere in the sequence for well-defined conjugation reactions 
and fusion of effector domains to the N- and/or C-termini [9,10], as 
there are no interfering cysteines or disulfide bonds in the protein 
molecule. 
Here we used the recently described DARPin fusion proteins with 
unstructured polypeptides [12] and introduced a single C-terminal 
Fig. 2. Cytotoxicity of DARPin-MMAF and PAS-DARPin-MMAF conjugates determined in XTT cell viability assays. The EpCAM-specific conjugates Ec1-MMAF and 
PAS-Ec1-MMAF were compared to the control conjugates Off7-MMAF, PAS-Off7-MMAF, and to free MMAF. EpCAM-positive cell lines were A) HT29 and B) SKBR3, 
in C) EpCAM-negative HEK293T cells were used as control. Cells were incubated with a serial dilution of the MMAF conjugates and free MMAF for 72 h before 
cytotoxicity was determined. Each data point corresponds to the mean of triplicate measurements ± SD. 
Table 2 
Cytotoxicitya of MMAF, DARPin-MMAF and PAS-DARPin-MMAF conjugates.      
Conjugate HT29 IC50b (M) SKBR3 IC50c (M) HEK293T IC50d (M)  
MMAF 4.65 × 10−08 1.70 × 10−08 8.36 × 10−08 
Ec1-MMAF 1.70 × 10−09 6.54 × 10−11 1.23 × 10−06 
PAS300-Ec1-MMAF 7.27 × 10−09 1.26 × 10−09 2.27 × 10−06 
PAS600-Ec1-MMAF 6.27 × 10−09 8.64 × 10−10 1.46 × 10−06 
PAS900-Ec1-MMAF 9.54 × 10−09 1.91 × 10−09 1.96 × 10−06 
Off7-MMAF 1.07 × 10−06 2.52 × 10−07 6.21 × 10−07 
PAS300-Off7-MMAF 3.41 × 10−06 2.46 × 10−07 1.08 × 10−06 
PAS600-Off7-MMAF 4.49 × 10−06 5.55 × 10−07 2.30 × 10−06 
PAS900-Off7-MMAF 1.63 × 10−04 9.48 × 10−07 1.80 × 10−06 
a cytotoxicity was determined in XTT cell viability assays (IC50: concentra-
tion at which cell viability was decreased by 50%). 
b HT29 is an EpCAM-positive cell line. 
c SKBR3 is an EpCAM-positive cell line. 
d HEK293T is an EpCAM-negative control cell line.  
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cysteine for facile conjugation of the cytotoxin MMAF with thiol-mal-
eimide chemistry [10,30] to generate a series of molecules with a range 
of molecular properties for systematic and comparative studies. As ex-
pected from previous results, the introduction of this conjugation site 
did not alter fundamental properties of the fusion proteins, such as 
expression, stability and cell binding, and resulted in homogeneous 
products with a defined 1:1 protein-to-drug ratio. The C-terminal 
MMAF with the maleimidocaproyl-linker adds an additional negative 
charge and increases the overall hydrophobicity of the otherwise hy-
drophilic fusion proteins. This feature of the polypeptide-DARPin- 
MMAF conjugates enabled us to prepare highly pure and molecularly 
defined products, either by anion exchange chromatography (AEX) or 
hydrophobic interaction chromatography (HIC). Sample preparation 
for HIC purification requires addition of high concentrations of am-
monium sulfate to the protein samples, which leads to non-specific 
adsorption to plastic and thus loss of large quantities of protein. 
Therefore, AEX was better suited for large-scale purification 
(70–100 mg) of mono-conjugated products. 
The purity of all preparations was > 95%. Electrospray ionization 
mass spectroscopy (ESI-MS) also confirmed the correct target masses, 
and that the samples consisted exclusively of the desired products, 
emphasizing the high purity of the mono-conjugates (Fig. 1C, Fig. S7,  
Table 1, Table S1). Surface plasmon resonance (SPR) also showed that 
conjugation of MMAF to the DARPin or the polypeptide-DARPin fusion 
proteins [12] did not affect binding affinity (Table 1, Table S1, Fig. S8). 
This high degree of product quality enabled us to investigate how 
Fig. 3. Tolerability of free MMAF, Ec1-MMAF and PAS-Ec1-MMAF conjugates in CD-1 nude mice. The conjugates were injected every other day for five times and the 
body weight was monitored daily. One week after the last injection, mice were euthanized and the blood was analyzed for levels of alanine aminotransferase activity 
(ALAT), leukocytes and thrombocytes. For each group, 3 mice were analyzed. 
F. Brandl, et al.   Journal of Controlled Release 327 (2020) 186–197
193
Fig. 4. Anti-tumor efficacy of the DARPin-MMAF and PAS-DARPin-MMAF conjugates in CD-1 nude mice. Mice (N = 6 mice per group) bearing EpCAM-positive 
HT29 tumor xenografts were injected every other day for five times with equimolar doses of 300 nmol/kg free MMAF, Ec1-MMAF, Off7-MMAF, and the PASylated 
conjugates or with 150 μL PBS as vehicle control. Arrows indicate days of injection. Tumor growth was monitored by caliper measurement during the course of 
50 days. Data points represent the mean tumor volume  ±  SEM of 6 mice. A) Tumor growth curves of all treatment groups, B) Kaplan-Meier survival plot with an 
endpoint defined as a tumor volume of 1000 mm3. C) Comparison of the tumor growth curves from mice treated with the size-matched EpCAM-targeting PAS-Ec1- 
MMAF and non-targeting control PAS-Off7-MMAF. 
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apparent molecular size affects half-life, tolerability, and anti-tumor 
efficacy. 
4.2. Cytotoxicity is in the low nM range and independent of polypeptide 
length and type 
As shown for antibody-MMAF [30] and DARPin-MMAF conjugates 
[10], upon internalization and lysosomal degradation, the cysteine- 
linked MMAF adduct is released into the cytosol to induce G2/M-phase 
arrest and apoptosis [33–35]. Here, we demonstrated EpCAM-specific 
killing of tumor target cells in the low nM range for all Ec1 DARPin- 
MMAF conjugates, independent of size, polypeptide type (XTEN or 
PAS) and length (XTEN288/PAS300, XTEN576/PAS600, XTEN864/ 
PAS900) (Fig. 2, Table 2, Fig. S9, Table S2). On the other hand, all non- 
targeting conjugates with control DARPin Off7 showed much lower 
cytotoxicity, which was also independent of EpCAM (Table 2, Table 
S2). As expected, free MMAF was also less potent, due to its negative 
charge, which decreases membrane permeability and reduces inter-
nalization by pinocytosis. 
The high potency and specificity of the EpCAM-targeting conjugates 
holds promise for better efficacy and tolerability in vivo, particularly for 
the polypeptide conjugates with high tumor localization and little non- 
specific accumulation in off-target tissues [12], as it will allow higher 
and repeated dosing. 
4.3. Mice tolerate repeated injection of 300 nmol/kg PAS-DARPin-MMAF 
Although the PASylated and XTENylated conjugates were equally 
potent in vitro, we focused on PAS-DARPin-MMAF for in vivo evaluation 
of tolerability and anti-tumor efficacy for several reasons. The PAS- 
DARPin-MMAF conjugates can be more easily produced at high yield 
and obtained in high purity by AEX, because the PAS-polypeptide lacks 
a negative charge, unlike XTEN, and the additional charge of MMAF 
can thus be used for separation of conjugate from non-conjugate. 
Systemic administration of cytotoxins is commonly associated with 
unwanted side-effects due to off-target toxicity to vital non-tumor tis-
sues [36], and this increases with increasing circulation time and dose. 
If toxicity increases more strongly than efficacy with molecular weight, 
this will narrow the therapeutic window. A few ADCs with MMAF have 
been approved for oncology indications due to their promising efficacy- 
to-tolerability profile [2,37]. Common side effects include thrombocy-
topenia, leukocytopenia and elevation of liver enzymes (ALAT, ASAT), 
all of which can be easily monitored in mice [38]. In mice, a maximum- 
tolerated dose of > 16 mg/kg (21 μmol/kg) free MMAF was determined 
[30], and in the same study an ADC with a drug-to-antibody ratio of 4.0 
was well tolerated at doses > 150 mg/kg (approx. 1 μmol/kg). Here, we 
used repeated dosing of 300 nmol/kg free MMAF, DARPin-MMAF and 
polypeptide-DARPin-MMAF conjugates injected every other day for five 
times, without observing changes in body weight or blood parameters 
(Fig. 3, Fig. S11). 
4.4. The anti-tumor efficacy of PAS-DARPin-MMAF conjugates has a 
molecular size optimum when injected in equimolar doses 
Using HT29 tumor xenografts in nude mice we systematically in-
vestigated the anti-tumor efficacy and tolerability of the MMAF con-
jugates of different sizes and serum half-lives, to investigate whether 
the benefit is simply proportional to half-life or whether there is an 
optimum. 
We found that the small size formats (free MMAF and DARPin- 
MMAF) had no anti-tumor efficacy (Fig. 4A, Fig. S12). In contrast, 
tumor control was achieved with all PASylated, half-life-extended 
conjugates (Fig. 4A,C). Importantly, the medium size conjugates 
PAS300-Ec1-MMAF and PAS600-Ec1-MMAF showed clearly more pro-
nounced effects than the larger PAS900-Ec1-MMAF. 
Various factors related to size are known to affect tumor targeting 
with drug conjugates. On the systemic level, they comprise extravasa-
tion, intratumoral distribution and tissue penetration, and excretion 
rate, which is the main factor influencing serum half-life. Cell binding 
affinity is linked to a phenomenon often called “binding-site barrier”, 
an observation that tight binding proteins will fully occupy the re-
ceptors, starting from the outside of the tumor and not reaching the 
inside. The suggestive name does not necessarily imply a physical 
barrier of the leading molecules for the molecules that follow [39,40]. 
On the cellular level, the rate of internalization and processing to re-
lease active drug [41,42] may also be related to molecular size para-
meters, and could thus potentially be rate-limiting and influence the 
efficacy on cells expressing the target. On the other hand, we could rule 
out affinity as a relevant parameter, as all constructs had essentially the 
same affinity. 
Thus, treatment success depends on a complex relationship of these 
factors with size. For example, large size prolongs half-life and thus 
creates a depot-effect of the circulation but, on the other hand, impairs 
extravasation and tissue penetration. Nonetheless, cellular effects were 
found to show no size dependence: the toxicity as a function of time was 
essentially the same for all PASylated constructs, independent of size 
(Fig. S10). 
Since clearly an optimum was found for efficacy in tumor control for 
the PASylated constructs of intermediate size (Fig. 4), as the efficacy 
decreased again with the longest PAS900 construct, we have to consider 
explanations within the systemic effect, and not reasons involving cel-
lular kinetics or molecular interactions. 
4.5. Localization and extravasation 
Although, in principle, MMAF and DARPin-MMAF conjugates are 
small enough to uniformly distribute in the xenografts, they have too a 
short half-live, due to rapid renal excretion, which impairs tumor tar-
geting [10]. Therefore, the overall level in the tumor is too low to 
control tumor growth (Fig. 4). 
For the EpCAM-targeting PAS-DARPin fusion proteins tumor loca-
lization increases with molecular size and was indeed highest for the 
PAS900 conjugate [12]. The reason why the PAS300 or PAS600 con-
jugates controlled tumor growth better than the PAS900 conjugate can 
thus not be explained by the overall tumor localization, but it is possible 
that upon extravasation more of the large conjugate is trapped in the 
perivascular space [43]. 
The extravasation rate depends on the fenestration of the vascular 
endothelium in the tumor [44–46]. A recent study demonstrated that 
the blood vessels in HT29 tumor xenografts in mice are well fene-
strated: a branched PEG40K conjugate with a molecular diameter of 
about 15 nm showed significantly higher tumor localization than na-
noparticles > 150 nm [47], indicating less hindered extravasation for 
molecules in this size range. This finding is also confirmed by mathe-
matical modeling and simulation data [45]. Differences in the extra-
vasation rate of the PAS-DARPin-MMAF conjugates are therefore likely 
to be only small, due to their comparatively small size with diameters of 
8 to 15 nm [12], which is below the pore size assumed for the fene-
strated tumor vasculature [44,45,48]. 
4.6. Intratumoral diffusion 
Upon extravasation, drug conjugates must evenly distribute in the 
tumor tissue to deliver the effector function to as many tumor cells as 
possible, and this process is dependent on the diffusion coefficient. 
While it is difficult to calculate a meaningful diffusion coefficient for a 
random flight polymer, such as PAS and XTEN, in dense tumor tissue, it 
is reasonable to assume that the diffusion coefficient will decrease with 
size [49,50]. This aspect is particularly important when MMAF is used 
as a cytotoxin, as it does not benefit from a bystander effect [30,51]. 
Studies with fluorescently labeled octyl chitosan nanocarriers in the 
range of 1 kDa to 300 kDa [43] and mathematical modeling and 
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simulation [21] are consistent with the expectation that intratumoral 
diffusion decreases with molecular size, even though the quantitative 
dependency for the random flight polymers is not clear. The modeling is 
also made difficult by inhomogeneous vascularization, mechanical ob-
stacles by the stroma and interstitial pressure [39]. Depending on the 
degree of tortuosity and size of the conjugate, diffusion rates in tumors 
can drop to very low levels [52]. 
In summary, due to the effect of effective molecular weight on the 
diffusion coefficient, intratumoral distribution and penetration are 
slowed down, favoring an uneven distribution, which makes treatment 
success unlikely. Thus, there seems to be a critical size where tumor 
drug load and tissue penetration are optimally balanced. 
4.7. Intra- and intermolecular blocking might enhance the effect of reduced 
diffusion coefficients 
We previously described that modification of binding proteins with 
a bulky polymer such as PEG can alter the binding kinetics by slight 
reduction of the association rate constant (ka), due to transient in-
tramolecular blocking of the paratope [53]. In addition, the polymer 
can cause intermolecular blocking of the epitope by “diagonal parking” 
on the cell surface and thus decrease the maximal number of receptors 
that can be engaged at any time. While slightly reduced association rate 
constants (ka) on EpCAM were measured for the polypeptide-DARPin 
fusion proteins [12] and here for the respective MMAF conjugates 
(Table 1, Table S1, Fig. S8), we conclude that these on-rate differences 
were irrelevant for intoxication (Fig. S10), since the cytotoxicity assay 
as a function of time showed no difference between the polymers of 
different length. Nonetheless, we cannot exclude that the effect of lower 
maximal loading (“diagonal parking”) with increased size might ne-
gatively affect anti-tumor efficacy in vivo. 
4.8. Perspectives 
Since the molecular size has an optimum, an obvious measure to 
enhance efficacy would be to introduce additional cysteines in the 
polypeptide sequence, thereby increasing the number of conjugated 
drug molecules at a given size. In a similar approach, XTEN polypep-
tides were loaded with multiple anti-retroviral peptides in one molecule 
[54] and, comparing this to the naked anti-retroviral peptide T-20 it-
self, it was shown that this increases serum half-life and solubility of the 
fairly insoluble peptide. Because of the hydrophilicity of XTEN, and 
probably PAS, several MMAF molecules can be conjugated without 
hampering the favorable properties of the molecule (F. Brandl, S. 
Busslinger et al., unpublished). Because of the excellent tolerability of 
the drug conjugates tested here, it is likely that they are far away from 
the maximal tolerated dose and that the drug load could thus be in-
creased. 
5. Conclusions 
We engineered a series of molecules which have exactly the same 
protein-to-drug ratio, the same attachment site and linker chemistry, 
the same epitope and affinity, and only differ by their effective mole-
cular size. We also generated a series of matching controls that are 
identical in all aspects except that they do not bind to the tumor cells — 
to account for any enhanced permeability and retention (EPR) effect 
independent of the actual direct cellular targeting. Our results clearly 
show that for cytotoxic protein-drug conjugates engineered for tumor 
targeting there is a size window where the efficacy is optimal. We 
conclude that this is primarily an effect of the counterbalancing effect 
of intratumoral diffusion and serum half-life. The effect of extravasation 
is considered small in the tumor model chosen, and our measurements 
indicate that the effects of on-rate (and thus affinity) on the cytotoxicity 
and anti-tumor efficacy are essentially negligible, and the maximal 
receptor loading effects (“diagonal parking”) do not influence toxicity 
conferred on tumor cells. 
While the present study has highlighted these dependencies, it will 
still be necessary in the near future to determine the actual optimum 
experimentally in preclinical tumor models, and it will be a further 
challenge to properly scale this to the clinical setting. Nonetheless, this 
study has illuminated that, in a given tumor model with its intrinsic 
anatomical and physiological properties, next to drug and linker con-
siderations, the actual pharmacokinetic and diffusion behavior of the 
protein-drug conjugate are of equal importance. 
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